Page 4 - B Pfizer News Today

Pfizer and BioNTech are reportedly preparing to ask the Food and Drug Administration to authorize a COVID-19 vaccine for kids younger than 5.

U.S. regulators are planning to review and authorize Pfizer and BioNTech's COVID-19 vaccine for children younger than 5 before data on a third -- and potentially necessary -- shot is available.

Pfizer and BioNTech on Tuesday launched a clinical study to evaluate the safety and efficacy of a COVID-19 vaccine that targets omicron, the globally dominant variant.

Pfizer has begun a study comparing its original COVID-19 vaccine with doses specially tweaked to match the hugely contagious omicron variant.

Pfizer and BioNTech on Tuesday launched a clinical study to evaluate the safety and efficacy of a COVID-19 vaccine that targets omicron, the globally dominant variant.

Pfizer has begun a study comparing its original COVID-19 vaccine with doses specially tweaked to match the hugely contagious omicron variant.

Two brand-new COVID-19 pills that were supposed to be an important weapon against the pandemic in the U.S. are in short supply and have played little role in the fight against the omicron wave of infections.

Two brand-new COVID-19 pills that were supposed to be an important weapon against the pandemic in the U.S. are in short supply and have played little role in the fight against the omicron wave of infections.

The FDA was just told by a federal judge that no, it can't take 75 years to release documents showing the process of Pfizer's COVID-19 vaccine licensing approval -- that it has to cough up the data within eight months. That's a significant win for open-government advocates.

Hospitalizations of U.S. children under 5 with COVID-19 soared in recent weeks to their highest level since the pandemic began, according to government data released Friday on the only age group not yet eligible for the vaccine.